Core Viewpoint - Anteris Technologies has secured a $90 million strategic investment from Medtronic, which follows a $320 million underwritten offering of common stock, aimed at advancing the global pivotal PARADIGM trial and commercializing the DurAVR® Transcatheter Heart Valve [1][3]. Group 1: Investment and Collaboration - The investment from Medtronic is seen as a significant milestone for Anteris, validating its program in the capital markets and indicating potential future collaborations [3]. - Anteris and Medtronic share a vision of advancing the Transcatheter Aortic Valve Replacement (TAVR) market through improved clinical science and valve design, focusing on durability and long-term patient outcomes [2][3]. Group 2: PARADIGM Trial - The PARADIGM Trial is a randomized controlled trial designed to evaluate the safety and effectiveness of the DurAVR® THV against existing TAVR options, with an enrollment target of approximately 1,000 patients [4][5]. - The trial will assess non-inferiority based on a primary composite endpoint that includes all-cause mortality, all strokes, and cardiovascular hospitalizations at one year post-procedure [5]. - Recruitment for the PARADIGM Trial has already begun, with the first patients enrolled in the fourth quarter of 2025 [6]. Group 3: Product Overview - Anteris' lead product, the DurAVR® Transcatheter Heart Valve, is designed to treat aortic stenosis and is the first biomimetic valve, aiming to replicate the performance of a healthy aortic valve [8]. - The DurAVR® THV is constructed from Anteris' patented ADAPT® tissue technology, which has been clinically used for over 10 years and is FDA-cleared, having been distributed to over 55,000 patients globally [8].

MINNEAPOLIS and BRISBANE, Australia, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) today released 30-day clinical outcomes for the DurAVR® THV in one hundred severe aortic stenosis patients with small aortic annuli (aortic annulus area 404 ± 37mm2). The DurAVR® THV demonstrated single digit mean gradients, large effective orifice areas (EOAs), no moderate or severe paravalvular leaks and no valve related mortality, with 97% freedom from ...